期刊文献+

人补体受体1型活性片段SCR15-18在毕赤酵母中的表达、纯化及活性鉴定 被引量:2

Expression,purification and activity identification of SCR15-18 domain of human complement receptor 1 in Pichia Pastoris
下载PDF
导出
摘要 目的实现人补体受体1型(complement receptor type 1,CR1)活性片段SCR15-18在毕赤酵母中的分泌表达。方法用PCR从原核表达质粒pET32a-sCR1-SCR15-18上扩增CR1-SCR15-18的编码基因,并克隆到毕赤酵母分泌表达质粒pPIC9,构建重组质粒pPIC9-CR1-SCR15-18,鉴定后测序;重组质粒电转化整合到毕赤酵母GS115基因组中,菌落PCR技术筛选阳性转化株;经摇瓶发酵和甲醇诱导,SDS-PAGE和Western blot鉴定目的蛋白的表达;Ni2+-NTA agarose亲和层析纯化目的蛋白,并用体外抑制补体溶血反应实验测定目的蛋白的生物活性。结果成功构建重组表达质粒pPIC9-CR1-SCR15-18;SDS-PAGE和Western blot证实目的基因在毕赤酵母中成功分泌表达;表达产物经镍柱快速纯化后,能够明显抑制补体的体外溶血。结论在毕赤酵母中成功实现了CR1-SCR15-18蛋白的分泌表达,该蛋白具有较高的抑制补体溶血的生物活性。 Objective To express the short consensus repeat 15-18 (SCR15-18) domain of human complement receptor 1 ( CR1 ) in Pichia pastoris as a secreted protein in order to found a base for large-scale industry fermentation. Methods The gene fragment of CR1-SCR15-18 was amplified by PCR from plasmid pET32a- sCR1-SCR15-18. The obtained sequence was subcloned into Pichia pastoris secretory expression vector pPIC9. After identification the recombinant plasmid pPICg-CR1-SCR15-18 was electrotransported into the yeast. Positive clones were identified using colony PCR. Positive recombinants were fermented in shake flaskes and induced with methanol. The recombinant proteins were identified with SDS-PAGE and Western blot analysis. After the recombinant protein was purified by Ni-NTA agarose metal chelate affinity chromatography, inhibiting complement hemolysis testing was used to detect the biological activity. Results Recombinant expression plasmid pPIC9-CR1-SCRIS-18 was successfully constructed. SDS-PAGE and Western blot analysis revealed that the target gene was successfully expressed in the yeast and the recombinant protein was successful secreted in the culture supernatant. After purification, the protein inhibited complement hemolysis in vitro. Conclusion CR1-SCR15-18 is successful expressed in Pichia Pastoris with high activity of inhibiting complement hemolysis.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2009年第6期470-473,共4页 Journal of Third Military Medical University
基金 国家自然科学基金(30471723) 重庆市自然科学基金(2007BB5011)~~
关键词 补体受体1型 毕赤酵母 分泌表达 补体溶血 complement receptor type 1 Pichia pastoris secretory expression complement hemolysis
  • 相关文献

参考文献12

  • 1Mollnes T E, Kirschfink M. Strategies of therapeutic complement inhibition[J].Mol Immunol, 2006, 43( 1 -2) : 107 - 121.
  • 2Krych-Goldberg M, Atkinson J P. Structure-function relationships of complement receptor type 1[J]. Immunol Rev, 2001, 180:112-122.
  • 3Lazar H L, Bokesch P M, van-Lenta F, et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass [ J ]. Circulation, 2004, 110(11 Suppl 1) : Ⅱ274 -Ⅱ279.
  • 4罗雪,汪正清.人sCR1结合C3b结构域基因的克隆及在大肠杆菌中高效表达[J].第三军医大学学报,2005,27(15):1551-1554. 被引量:7
  • 5谭兵,张德纯,汪正清.重组人可溶性补体受体1型SCR15-18片段表达纯化及生物活性鉴定[J].第三军医大学学报,2007,29(10):892-895. 被引量:6
  • 6Daly R, Hearn M T. Expression of heterologous proteins in Pichia pastoffs: a useful experimental tool in protein engineering and production [J]. J Mol Recognit, 2005, 18(2): 119 -138.
  • 7Yin J, Li G, Ren X, et al. Select what you need : a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes [J]. J Bioteehnol, 2007, 127 ( 3 ) : 335 - 347.
  • 8Souza D G, Esser D, Bradford R, et al. APT070 (Mimcocept) , a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury [ J ]. Br J Pharmacol, 2005, 145(8) : 1027 - 1034.
  • 9谭兵,兰阳军,张德纯,汪正清.重组人可溶性补体受体1型SCR15-18片段对心肌缺血再灌注损伤的保护作用[J].中华心血管病杂志,2007,35(11):1037-1040. 被引量:11
  • 10Blanchard V, Gadkari R A, George A V, et al. High-level expression of biologically active glycoprotein hormones in Pichia pastoris strainsselection of strain GS115, and not X-33, for the production of biologi- cally active N-glycosylated 15N-labeled phCG [ J ]. Glycoconj J, 2008, 25 (3) : 245 - 257.

二级参考文献32

  • 1罗雪,汪正清.人sCR1结合C3b结构域基因的克隆及在大肠杆菌中高效表达[J].第三军医大学学报,2005,27(15):1551-1554. 被引量:7
  • 2罗雪,汪正清.补体受体1型的结构功能及sCR1基因克隆表达的策略[J].创伤外科杂志,2005,7(6):475-477. 被引量:1
  • 3谭兵,张德纯,汪正清.重组人可溶性补体受体1型SCR15-18片段表达纯化及生物活性鉴定[J].第三军医大学学报,2007,29(10):892-895. 被引量:6
  • 4萨姆布鲁克J 拉塞尔DW 黄培堂 译.分子克隆实验指南[M](第3版)[M].北京:科学出版社,2002.463-465.
  • 5Stahl G L, Xu X, Hao L, et al. Role for the alternative complement pathway in ischemia/reperfusion injury [J]. Am J Pathol, 2003, 162 (2): 449 -455.
  • 6Noriyuki I, Hisamune K, Wang P C. Observation by electron microscopy on recombinant soluble human complement receptor type 1 ( sCR1 ) and its derivative, aglyco-sCR1, from CHO cells [ J ]. Enzyme and Microbial Technology, 2003, 33 (4): 482 -487
  • 7Mizuno M, Nishikawa K, Okada N, et al. Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following Lipopolysaccharide priming [ J ]. Int Arch Allergy Immunol,2002, 127 (1): 55-62.
  • 8Azimzadeh A, Zorn G L3rd, Blair K S, et al. Hyperacute lung rejection in the pig-to-human model. 2. Synergy between soluble and membrane complement inhibition [ J ]. Xenotransplantation, 2003, 10 (2): 120 - 131.
  • 9Dodd I, Mossakowska D E, Camilleri P, et al. Overexpression in Escherichia coli, folding, purification, and characterization of the first three short consensus repeat modules of human complement receptor type 1 [J]. Protein Expr Purif, 1995, 6 (6): 727 -736.
  • 10Mossakowska D, Dodd I, Pindar W, et al. Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation[J]. Eur J Immunol, 1999, 29 (6): 1955-1965.

共引文献37

同被引文献24

  • 1Nakao A,Kaczorowskil DJ,Sugimoto R,et al.Application of heme oxygenase-1,carbon monoxide and biliverdin for the prevention of intestinal ischemin/reperfusion injury[J].J Clin Biochem Nutr,2008,42 (2):78-88.
  • 2Grootjans J,Lenaerts K,Derikx JP,et al.Human intestinal ischemia-reperfusion-induced inflammation characterized:experiences from a new translational model[J].Am J Pathol,2010,176(5):2283-2291.
  • 3Woods KM,Pope MR,Hoffman SM,et al.CR2+ marginal zone B cell production of pathogenic natural antibodies is C3 independent[J].J Immunol,2011,186(3):1755-1762.
  • 4Davis AE 3rd,Lu F,Mejia P.C1 inhibitor,a multi-functional serine protease inhibitor[J].Thromb Haemost,2010,104(5):886-893.
  • 5Lee H,Green DJ,Lai L,et al.Early complement factors in the local tissue immunocomplex generated during intestinal ischemia/ reperfusion injury[J].Mol Immunol,2010,47(5):972-981.
  • 6Souza DG,Esser D,Bradford R,et al.APT070 (Mirococept),a membrane-localised complement inhibitor,inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury[J].Br J Pharmacol,2005,145(8):1027-1034.
  • 7Chiu CJ,McArdle AH,Brown R,et al.Intestinal mucosal lesion in low-flow states.I.A morphological,hemodynamic,and metabolic reappraisal[J].Arch Surg,1970,101(4):478-483.
  • 8Fleming SD,Hylton D,Hoffman S,et al.CR2 targeted complement inhibitors attenuate intestinal damage[J].Mol Immunol,2010,47(13):2277.
  • 9Furtado PB,Huang CY,Ihyembe D,et al.The partly folded back solution structure arrangement of the 30 SCR domains in human complement receptor type 1 (CR1) permits access to its C3b and C4b ligands[J].J Mol Biol,2008,375(1):102-118.
  • 10Acosta J,Qin X,Halperin J.Complement and complement regulatory proteins as potential molecular targets for vascular diseases[J].Curr Pharm Des,2004,10(2):203-211.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部